MRaganGreenJr.MD

Orthopaedic Surgery • Shreveport, LA

Physician

Join to view full profile

Are you Dr. Green?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 37 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1455 E Bert Kouns Loop
Shreveport, LA 71105
Phone+1 318-798-4623

Fax+1 318-798-4639
Is this information wrong?

Summary

Dr. M Green Jr., MD is a board certified orthopedic surgeon in Shreveport, Louisiana.

Education & Training

Louisiana State UniversityResidency, Orthopaedic Surgery, 1975 - 1979
Louisiana State University (Shreveport)Internship, Orthopaedic Surgery, 1974 - 1975
Louisiana State University School of Medicine in New OrleansClass of 1974

Certifications & Licensure

American Board of Orthopaedic Surgery Orthopaedic Surgery

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012

Publications & Presentations

PubMed

The role of ATF/CREB family members in cell growth, survival and apoptosis.
Persengiev, S.P., Green, M.R.> ;Apoptosis. 2003 Jun
Nutrigenetics: where next for the foods industry?
Green, M.R., van der Ouderaa, F.> ;Pharmacogenomics J. 2003
A novel peptide recognition mode revealed by the X-ray structure of a core U2AF35/U2AF65 heterodimer.
Kielkopf, C.L., Rodionova, N.A., Green, M.R., Burley, S.K.> ;Cell. 2001 Sep 7
Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation.
Devireddy, L.R., Teodoro, J.G., Richard, F.A., Green, M.R.> ;Science. 2001 Aug 3
SAGA is an essential in vivo target of the yeast acidic activator Gal4p.
Bhaumik, S.R., Green, M.R.> ;Genes Dev. 2001 Aug 1
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Rocha Lima, C.M., Urbanic, J.J., Lal, A., Kneuper-Hall, R., Brunson, C.Y., Green, M.R.> ;Semin Oncol. 2001 Jun
Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection.
Purohit, P., Dupont, S., Stevenson, M., Green, M.R.> ;RNA. 2001 Apr
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
Breathnach, O.S., Freidlin, B., Conley, B., Green, M.R., Johnson, D.H., Gandara, D.R., O'Connell, M., Shepherd, F.A., Johnson, B.E.> ;J Clin Oncol. 2001 Mar 15
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
Rocha Lima, C.M., Sherman, C.A., Brescia, F.J., Brunson, C.Y., Green, M.R.> ;Oncology (Williston Park). 2001 Mar
Cerebral venous thrombosis as a complication of Crohn disease: a case report.
Al-Malik, H., Green, M.R.> ;J Pediatr Gastroenterol Nutr. 2001 Feb
Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer.
Niell, H.B., Perry, M.C., Clamon, G., Crawford, J., Miller, A.A., Herndon, J., Green, M.R.> ;Clin Lung Cancer. 2001 Feb
Rapid identification and characterization of hammerhead-ribozyme inhibitors using fluorescence-based technology.
Jenne, A., Hartig, J.S., Piganeau, N., Tauer, A., Samarsky, D.A., Green, M.R., Davies, J., Famulok, M.> ;Nat Biotechnol. 2001 Jan
Identification and characterization of yUAP/Sub2p, a yeast homolog of the essential human pre-mRNA splicing factor hUAP56.
Zhang, M., Green, M.R.> ;Genes Dev. 2001 Jan 1
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Rocha Lima, C.M., Urbanic, J.J., Sherman, C.A., Brescia, F.J., Green, M.R.> ;Oncology (Williston Park). 2001 Jan
Irinotecan in the management of patients with pancreatic cancer.
Green, M.R., Harper, M., Safa, A., Sherman, C.A., Mushtaq, C.M., Bahadori, H., Brescia, F.J., Rocha Lima, C.M.> ;Oncology (Williston Park). 2000 Dec
Future randomized trials for non small-cell lung cancer.
Green, M.R.> ;Clin Lung Cancer. 2000 Dec
Radiation and chemotherapy for patients with stage III non-small cell lung cancer.
Green, M.R., Rocha Lima, C.M., Sherman, C.A.> ;Semin Radiat Oncol. 2000 Oct
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Cappuzzo, F., Rocha Lima, C.M., Sherman, C.A., Green, M.R.> ;Oncology (Williston Park). 2000 Jul
Differential recognition of the polypyrimidine-tract by the general splicing factor U2AF65 and the splicing repressor sex-lethal.
Singh, R., Banerjee, H., Green, M.R.> ;RNA. 2000 Jun
Distinct classes of yeast promoters revealed by differential TAF recruitment.
Li, X.Y., Bhaumik, S.R., Green, M.R.> ;Science. 2000 May 19
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukem...
Kindler, H.L., Belani, C.P., Herndon, J.E., Vogelzang, N.J., Suzuki, Y., Green, M.R.> ;Cancer. 1999 Nov 15
Profound misregulation of muscle-specific gene expression in facioscapulohumeral muscular dystrophy.
Tupler, R., Perini, G., Pellegrino, M.A., Green, M.R.> ;Proc Natl Acad Sci U S A. 1999 Oct 26
3 citations
Current strategies for locoregionally advanced unresectable non-small cell lung cancer.
Everett E. Vokes, M. R. Green> ;Seminars in Oncology. 1999 Oct 1
Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
Rocha Lima, C.M., Eckardt, J.R., Leong, S.S., Sherman, C.A., Perkel, J.A., Putman, T., Safa, A.R., Bahadori, H.R., Green, M.R.> ;Semin Oncol. 1999 Oct
A human nuclear-localized chaperone that regulates dimerization, DNA binding, and transcriptional activity of bZIP proteins.
Virbasius, C.M., Wagner, S., Green, M.R.> ;Mol Cell. 1999 Aug
Join now to see all